Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Kiniksa Pharmaceuticals International (KNSA) Leases (2021 - 2025)

Kiniksa Pharmaceuticals International's Leases history spans 5 years, with the latest figure at $9.8 million for Q4 2025.

  • For Q4 2025, Leases fell 5.48% year-over-year to $9.8 million; the TTM value through Dec 2025 reached $9.8 million, down 5.48%, while the annual FY2025 figure was $9.8 million, 5.48% down from the prior year.
  • Leases reached $9.8 million in Q4 2025 per KNSA's latest filing, down from $10.1 million in the prior quarter.
  • In the past five years, Leases ranged from a high of $13.2 million in Q2 2023 to a low of $4.1 million in Q2 2022.
  • Average Leases over 5 years is $8.6 million, with a median of $9.9 million recorded in 2025.
  • Peak YoY movement for Leases: fell 24.45% in 2022, then soared 224.18% in 2023.
  • A 5-year view of Leases shows it stood at $5.6 million in 2021, then decreased by 2.97% to $5.4 million in 2022, then soared by 121.56% to $11.9 million in 2023, then dropped by 13.03% to $10.4 million in 2024, then dropped by 5.48% to $9.8 million in 2025.
  • Per Business Quant, the three most recent readings for KNSA's Leases are $9.8 million (Q4 2025), $10.1 million (Q3 2025), and $10.3 million (Q2 2025).